Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026

Audio By Carbonatix

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK / ACCESS Newswire / June 17, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces that it has been invited to present data from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical study at the Animal Longevity Summit ("ALOS"), taking place in Toronto, Canada, on 1-2 October 2026.

The SLAB study is designed to evaluate the potential of Genflow's centenarian SIRT6 gene therapy to address multiple hallmarks of aging and age-related decline in companion animals. The presentation is expected to provide one of the most comprehensive datasets generated to date from the Company's veterinary longevity programme and forms part of Genflow's broader strategy to develop therapies targeting fundamental biological mechanisms associated with aging, with applications in both veterinary and human health.

ALOS is the first conference dedicated exclusively to animal longevity and is expected to bring together leading researchers, veterinary scientists, biotechnology companies, and investors focused on extending healthy lifespan in companion animals. Confirmed speakers include Dr. Matt Kaeberlein, Dr. Vera Gorbunova, Dr. Aubrey de Grey, Liz Parrish, Dr. Noah Davidsohn, and Dr. Varun Dwaraka.

Further details regarding the presentation schedule will be announced by the conference organisers.

Dr. Eric Leire, Chief Executive Officer of Genflow, commented: "We are pleased to have been invited to present our SLAB study findings at the Animal Longevity Summit, a leading forum dedicated to advancing the science of healthy aging in companion animals. The study represents an important step in evaluating the potential of our proprietary centenarian SIRT6 gene therapy approach in a real-world aging model. We look forward to sharing the data with researchers, veterinarians, industry participants and investors focused on the emerging longevity sector."

About the SLAB Study

The SLAB (Sarcopenia and Longevity in Aged Beagles) study is evaluating the safety and biological activity of Genflow's proprietary SIRT6 centenarian gene therapy in aged beagles. The study began in March 2025 and ends in June 2026.

Contacts

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic

liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Genflow Biosciences PLC